Advanced search
Publication Cover
Drug Development and Industrial Pharmacy Volume 38, 2012 - Issue 12
Submit an article Journal homepage
2,927
Views
14
CrossRef citations to date
0
Altmetric
Research Article

Development of orally disintegrating tablets comprising controlled-release multiparticulate beads

Gopi M. VenkateshAptalis Pharma (formerly Eurand, Inc.) R & D, Vandalia, OH 45377, USCorrespondence[email protected]
,
Phillip J. StevensAptalis Pharma (formerly Eurand, Inc.) R & D, Vandalia, OH 45377, US
&
Jin-Wang LaiAptalis Pharma (formerly Eurand, Inc.) R & D, Vandalia, OH 45377, US
Pages 1428-1440 | Received 04 Oct 2011, Accepted 20 Dec 2011, Published online: 23 Feb 2012

References

  • Christensen I, Geismar L, Kirkegaard A, Kirkegaard G. (1986). Additional studies on side effects of melperone in long-term therapy for 1-20 years in psychiatric patients. Arzneimittelforschung, 36:855–860.
  • Barbato L, Monge A, Stocchi F, Nordera G. (1996). Melperone in the treatment of iatrogenic psychosis in Parkinson’s disease. Funct Neurol, 11:201–207.
  • Meltzer HY, Sumiyoshi T, Jayathilake K. (2001). Melperone in the treatment of neuroleptic-resistant schizophrenia. Psychiatry Res, 105:201–209.
  • Fernandez HH, Trieschmann ME, Friedman JH. (2003). Treatment of psychosis in Parkinson’s disease: safety considerations. Drug Saf, 26:643–659.
  • Sumiyoshi T, Jayathilake K, Meltzer HY. (2003). A comparison of two doses of melperone, an atypical antipsychotic drug, in the treatment of schizophrenia. Schizophr Res, 62:65–72.
  • Borgström L, Larsson H, Molander L. (1982). Pharmacokinetics of parenteral and oral melperone in man. Eur J Clin Pharmacol, 23:173–176.
  • Molander L, Borgström L. (1983). Sedative effects and prolactin response to single oral doses of melperone. Psychopharmacology (Berl), 79:142–147.
  • Venkatesh, G., 2009, Diffucaps® technology for controlled release drug delivery, in: Youan, Bi-Botti C. (ed), Chronotherapeutics: Science and Technology for biological rhythm-guided therapy and prevention of Diseases. John Wiley & Sons, Inc., New York, pp. 121–144.
  • Venkatesh, G.M., Qian, K.K., Vangala, S., Clevenger, J.M., Guenther, D., 2005. Orally disintegrating tablets and methods of manufacture. US patent # “20050232988 A1”.
  • Venkatesh, G., 2010, Granulation approaches for orally disintegrating formulations, in: Parikh, D.M. (ed), Handbook of Pharmaceutical Granulation Technology, Third Edition. Informa Healthcare, Inc., New York, pp. 401–434.
  • Morimoto K., Watanabe Y., Sanada Y., Miwa T., Masada T., 1997. Rotary type tableting machine with lubricant spraying means, assigned to Kyowa Hakko Kogyo Co. US patent “5,700,492”.
  • Papp, M.K., Venkatesh, G.M., Harmon, T. 2010. Specialized techniques for developing ODT dosage forms. On Drug Delivery. April, 8-10, (http://www.ondrugdelivery.com/products/current_issues.htm).
  • Pfister, W.R., Ghosh, T.K., 2005. Orally disintegrating tablets: products, technologies, and development issues Pharm Technol 29, 136–150.
  • SQC Online. ANSI/ASQ Z1.4 Sampling plan for attribute data. (http://www.sqconline.com/mil-std-105.html). Accessed November 2010.
  • Yarwood, R., 1990, Zydis – a novel fast dissolving dosage form. Manuf Chem. 61, 36–37.
  • Lindgren, S., Janzon, L., 1993. Dysphagia: prevalence of swallowing complaints and clinical findings. Med Clin North Am. 77, 3–5.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.